Notable Labs EBITDA Margin 2013-2024 | NTBLQ
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Notable Labs (NTBLQ) over the last 10 years. The current EBITDA margin for Notable Labs as of June 30, 2024 is .
| Notable Labs EBITDA Margin Historical Data |
| Date |
TTM Revenue |
TTM EBITDA |
EBITDA Margin |
| 2022-12-31 |
$-0.00B |
$-0.01B |
1200.00% |
| 2022-09-30 |
$0.00B |
$-0.04B |
inf% |
| 2022-06-30 |
$0.00B |
$-0.03B |
inf% |
| 2022-03-31 |
$0.00B |
$-0.03B |
inf% |
| 2021-12-31 |
$0.00B |
$-0.03B |
inf% |
| 2021-09-30 |
$0.00B |
$-0.03B |
inf% |
| 2021-06-30 |
$0.00B |
$-0.03B |
inf% |
| 2021-03-31 |
$0.00B |
$-0.03B |
inf% |
| 2020-12-31 |
$0.00B |
$-0.02B |
inf% |
| 2020-09-30 |
$0.00B |
$-0.02B |
inf% |
| 2020-06-30 |
$0.00B |
$-0.02B |
inf% |
| 2020-03-31 |
$0.00B |
$-0.02B |
inf% |
| 2019-12-31 |
$0.00B |
$-0.02B |
inf% |
| 2019-09-30 |
$0.00B |
$-0.02B |
inf% |
| 2019-06-30 |
$0.00B |
$-0.02B |
inf% |
| 2019-03-31 |
$0.00B |
$-0.02B |
inf% |
| 2018-12-31 |
$0.00B |
$-0.02B |
inf% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.000B |
|
Notable Labs Ltd. is a clinical-stage platform therapeutics company developing predictive precision medicines for patients with cancer. Notable Labs Ltd., formerly known as Vascular Biogenics Ltd., is based in FOSTER CITY, Calif.
|
